title: Interaction between orexin A and cannabinoid system in the lateral hypothalamus of rats and effects of subchronic intraperitoneal administration of cannabinoid receptor inverse agonist on food intake and the nutritive utilization of protein.
abstract: Crosstalk may occur between cannabinoids and other systems controlling appetite, since cannabinoid receptors are present in hypothalamic circuits involved in feeding regulation, and likely to interact with orexin. In this study, an immunohistochemical approach was used to examine the effect of the intracerebroventricular administration of cannabinoid receptor inverse agonist AM 251 on orexin neuropeptide in the hypothalamic system. AM-activated neurons were identified using c-Fos as a marker of neuronal activity. The results obtained show that AM 251 decreases orexin A immunoreactivity, and that it increases c-Fos-immunoreactive neurons within the hypothalamus when compared with the vehicle-injected control group. We also studied the effects of subchronic intraperitoneal administration of AM 251 on food intake, body weight, and protein utilization. The administration of AM 251 at 1, 2, or 5 mg/kg led to a significant reduction in food intake, along with a significant decrease in the digestive utilization of protein in the groups injected with 1 and 2 mg/kg. There was a dose-related slowdown in weight gain, especially at the doses of 2 and 5 mg/kg, during the initial days of the trial. The absence of this effect in the pair-fed group reveals that any impairment to digestibility was the result of administering AM 251. These data support our conclusion that hypothalamic orexigenic neuropeptides are involved in the reduction of appetite and mediated by the cannabinoid receptor inverse agonist. Furthermore, the subchronic administration of AM 251, in addition to its effect on food intake, has significant effects on the digestive utilization of protein.
authors.affiliation: Department of Physiology, School of Pharmacy, University of Granada, Granada, Spain. mlopezj@ugr.es.
authors.forename: I
authors.initials: I
authors.lastname: Merroun
authors.forename: N
authors.initials: N
authors.lastname: El Mlili
authors.forename: R
authors.initials: R
authors.lastname: Martinez
authors.forename: J M
authors.initials: JM
authors.lastname: Porres
authors.forename: J
authors.initials: J
authors.lastname: Llopis
authors.forename: H
authors.initials: H
authors.lastname: Ahabrach
authors.forename: P
authors.initials: P
authors.lastname: Aranda
authors.forename: C
authors.initials: C
authors.lastname: Sanchez Gonzalez
authors.forename: M
authors.initials: M
authors.lastname: Errami
authors.forename: M
authors.initials: M
authors.lastname: Lopez-Jurado
mesh_terms: D000818:Animals; D001835:Body Weight / Q000187:drug effects; D063386:Cannabinoid Receptor Agonists / Q000494:pharmacology*; D002186:Cannabinoids / Q000378:metabolism*; D004435:Eating / Q000187:drug effects*; D007026:Hypothalamic Area, Lateral / Q000187:drug effects* / Q000378:metabolism; D007274:Injections, Intraperitoneal / Q000379:methods; D008297:Male; D009474:Neurons / Q000187:drug effects / Q000378:metabolism; D000068797:Orexins / Q000378:metabolism*; D010880:Piperidines / Q000494:pharmacology; D011506:Proteins / Q000378:metabolism*; D016760:Proto-Oncogene Proteins c-fos / Q000378:metabolism; D011720:Pyrazoles / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D043882:Receptors, Cannabinoid / Q000378:metabolism*
chemical_list: D063386:Cannabinoid Receptor Agonists; D002186:Cannabinoids; D000068797:Orexins; D010880:Piperidines; D011506:Proteins; D016760:Proto-Oncogene Proteins c-fos; D011720:Pyrazoles; D043882:Receptors, Cannabinoid; C103505:AM 251